Table 1.
Lectin pathway components involved in human diseases and LP-related drugs in clinical or preclinical trials.
| Disorders | LP Components Involved |
Drugs under Clinical Trial | Drug Candidates under Preclinical Trial |
|---|---|---|---|
| Renal disorders | |||
| IgA nephropathy | MBL, ficolin-2, MASP-1, MASP-2, MASP-3, MAP-19 [145,146,147,148,149] | Narsoplimab (recently discontinued) [150,151] |
Anti-MASP-3 (OMS906) [152] |
| Membranous nephropathy | MBL, MASP-1, MASP-2 [153,154,155,156] |
Narsoplimab [157] | |
| Diabetic kidney disease | MBL, ficolin-3 [158,159] | Anti-MBL MAb [160] | |
| Ischemia Reperfusion Injury | |||
| Renal IRI | MBL, CL-K1, MASP-2 [76,77,78,161,162,163,164,165] |
CL-K1 inhibition by L-fucose; C1INH; TFMI-2 [166,167,168,169] |
|
| Myocardial IRI | MBL, ficolin-2, MASP-1, MASP-2 [138,170,171,172,173,174,175,176] |
C1INH; anti-MBL MAb [177,178] | |
| Ischemic stroke | MBL, MASP-1, MASP-2 [179,180,181,182] | ||
| Atherosclerosis | MBL, ficolin-1, ficolin-2, ficolin-3, MASP-3 [183,184,185] | ||
| COVID-19 | MBL, ficolin-2, ficolin-3, MASP-2 [186,187,188,189,190,191] |
Narsoplimab * [192] | |
| Hereditary angioedema | MASP-1 [193,194] | C1INH (approved) ** [195] | |
| Schizophrenia | MBL, ficolin-2, MASP-2 [59,196] |
* Target: MASP-2; ** Main targets: kallikrein and FXIIa.